$0.9515
-0.0211-2.17%
Lineage Cell Therapeutics (LCTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.02 | $-0.03 | $-0.05 | $-0.02 |
| Actual | $-0.03 | $-0.03 | $0.00 | $-0.13 |
| Surprise | -50.0% | 0.00% | +108.0% | -550.0% |
| Revenue | ||||
| Estimate | $5.2M | $3.1M | $2.1M | $2.4M |
| Actual | $1.1M | $1.7M | $6.6M | $3.7M |
| Surprise | -79.6% | -44.5% | +214.9% | +51.8% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.03 | $0.01 | $-0.03 | $-0.03 |
| Revenue | ||||
| Consensus | $2.3M | $9.9M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.03 | $-0.02 | -50.0 % |
| Q1 | May 12, 2026 | $-0.03 | $-0.03 | 0.00 % |
| Q4 | Mar 5, 2026 | $0.00 | $-0.05 | 108.0 % |
| Q3 | Nov 6, 2025 | $-0.13 | $-0.02 | -550.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $1.07M | $5.23M | -79.6 % |
| Q1 | May 12, 2026 | $1.73M | $3.11M | -44.5 % |
| Q4 | Mar 5, 2026 | $6.60M | $2.10M | 214.9 % |
| Q3 | Nov 6, 2025 | $3.68M | $2.43M | 51.8 % |